Envestnet Asset Management Inc. Purchases 5,656 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Envestnet Asset Management Inc. boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 35.5% in the second quarter, HoldingsChannel.com reports. The firm owned 21,591 shares of the company’s stock after acquiring an additional 5,656 shares during the period. Envestnet Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $3,495,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Slow Capital Inc. raised its holdings in CRISPR Therapeutics by 0.5% in the first quarter. Slow Capital Inc. now owns 16,387 shares of the company’s stock worth $2,369,000 after purchasing an additional 87 shares in the last quarter. Golden Green Inc. raised its holdings in CRISPR Therapeutics by 5.4% in the second quarter. Golden Green Inc. now owns 1,758 shares of the company’s stock worth $285,000 after purchasing an additional 90 shares in the last quarter. Montag A & Associates Inc. raised its holdings in CRISPR Therapeutics by 2.5% in the second quarter. Montag A & Associates Inc. now owns 4,194 shares of the company’s stock worth $679,000 after purchasing an additional 102 shares in the last quarter. Huntington National Bank grew its stake in shares of CRISPR Therapeutics by 55.2% during the second quarter. Huntington National Bank now owns 450 shares of the company’s stock worth $73,000 after acquiring an additional 160 shares during the last quarter. Finally, Sowell Financial Services LLC grew its stake in shares of CRISPR Therapeutics by 29.3% during the first quarter. Sowell Financial Services LLC now owns 715 shares of the company’s stock worth $77,000 after acquiring an additional 162 shares during the last quarter. Institutional investors and hedge funds own 52.68% of the company’s stock.

In other news, CEO Samarth Kulkarni sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 4th. The stock was sold at an average price of $125.02, for a total transaction of $187,530.00. Following the completion of the transaction, the chief executive officer now directly owns 189,219 shares of the company’s stock, valued at approximately $23,656,159.38. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Bradley J. Phd Bolzon sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 19th. The stock was sold at an average price of $126.43, for a total value of $1,264,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 106,875 shares of company stock valued at $15,362,110. Corporate insiders own 10.70% of the company’s stock.

CRISPR Therapeutics stock opened at $116.30 on Wednesday. CRISPR Therapeutics AG has a 12 month low of $79.31 and a 12 month high of $220.20. The stock’s 50 day simple moving average is $126.62 and its two-hundred day simple moving average is $124.38. The firm has a market cap of $8.86 billion, a PE ratio of 22.76 and a beta of 2.25.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, July 29th. The company reported $9.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.52 by $5.92. The business had revenue of $900.70 million for the quarter, compared to analyst estimates of $678.05 million. CRISPR Therapeutics had a return on equity of 24.08% and a net margin of 49.52%. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post 4.81 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the company. Chardan Capital dropped their price target on CRISPR Therapeutics from $175.00 to $171.00 and set a “buy” rating on the stock in a research note on Friday, July 30th. TheStreet upgraded CRISPR Therapeutics from a “d” rating to a “c+” rating in a research note on Monday, August 9th. Citigroup upgraded CRISPR Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $55.00 to $132.00 in a research note on Monday, June 14th. upgraded CRISPR Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $55.00 to $132.00 in a research note on Monday, June 14th. Finally, Canaccord Genuity upped their target price on CRISPR Therapeutics from $151.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, August 16th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $160.00.

About CRISPR Therapeutics

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

See Also: Return on Equity (ROE)

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.